# US 2018/0023062 A1 · Compositions and methods for custom site-specific dna recombinases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023062 A1
- Document ID: US20180023062A1
- Status: Published application
- Kind: A1
- Application number: 15/633,591
- Filed: 2017-06-26
- Published: 2018-01-25
- Earliest claimed: 2012-12-18
- Assignees: Monsanto Technology LLC
- Applicants: Monsanto Technology LLC
- Inventors: Jonathan C. Lamb; Artem G. Evdokimov
- Web page: https://patentgrep.com/patent/US20180023062A1

## CPC

- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C07K 14/4705: {stimulating, promoting or activating activity}
- C12N 15/8213: {Targeted insertion of genes into the plant genome by homologous recombination}
- C12N 15/902: {using homologous recombination}
- C07K 2319/00: Fusion polypeptide
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to biotechnology and provides novel compositions and methods for sequence-specific or sequence-directed transcription activator-like effector recombinases. The invention also provides novel plant transformation vectors and expression cassettes, which include novel combinations of chimeric recombinases with plant expression and transformation elements. Methods for gene-targeting, DNA sequence removal, and molecular breeding are also provided.

## Claims

### Claim 1

A DNA construct encoding a chimeric recombinase polypeptide comprising a serine recombinase catalytic domain and a TALE DNA-domain comprising at least one repeat-variable di-residue (RVD) DNA-binding repeat domain.

### Claim 2 (depends on 1)

The DNA construct of claim 1, comprising a nucleic acid encoding a polypeptide linker, wherein the linker is between the serine recombinase catalytic domain and the TALE DNA-binding domain.

### Claim 3 (depends on 1)

The DNA construct of claim 1, wherein the serine recombinase catalytic domain is positioned at an N-terminal position of the chimeric recombinase polypeptide.

### Claim 4 (depends on 1)

The DNA construct of claim 1, wherein the serine recombinase catalytic domain comprises a small serine recombinase catalytic domain.

### Claim 5 (depends on 4)

The DNA construct of claim 4, wherein the small serine recombinase catalytic domain is a permissive small serine recombinase catalytic domain.

### Claim 6 (depends on 4)

The DNA construct of claim 4, wherein the small serine recombinase catalytic domain is a recombinase selected from the group consisting of Gin20H106Y, GinL7C7-EE2, GinL7C7-EE3, HinC, and HinB (HinH106Y).

### Claim 7 (depends on 1)

The DNA construct of claim 1, wherein the TALE DNA-binding domain is positioned at a C-terminal position of the chimeric recombinase polypeptide.

### Claim 8 (depends on 1)

The DNA construct of claim 1, wherein the TALE DNA-binding domain of said chimeric recombinase polypeptide retains equal or greater binding affinity relative to a TALE DNA-binding domain lacking said recombinase catalytic domain.

### Claim 9 (depends on 1)

The DNA construct of claim 1, wherein a first amino acid of the TALE DNA-binding domain begins 40 to about 160 amino acids upstream from a first amino acid of a first at least one RVD DNA-binding repeat domain.

### Claim 10 (depends on 1)

The DNA construct of claim 1, wherein a first amino acid of the TALE DNA-binding domain begins 53, 81, 85, 98, 102, 113, 117, 130, 136, or 147 amino acids upstream from a first amino acid of a first at least one RVD DNA-binding repeat domain.

### Claim 11 (depends on 2)

The DNA construct of claim 2, wherein the linker comprises at least 2 amino acids.

### Claim 12 (depends on 1)

The DNA construct of claim 1, wherein the chimeric recombinase polypeptide is a permissive recombinase.

### Claim 13 (depends on 2)

The DNA construct of claim 2, wherein the linker comprises about 4 amino acids to about 30 amino acids, wherein the linker is between the serine recombinase catalytic domain and the TALE DNA-binding domain.

### Claim 14 (depends on 12)

The DNA construct of claim 12, wherein the permissive recombinase comprises:
a) a small serine recombinase catalytic domain of the type GinL7C7-EE2 positioned at the N-terminal position; and
b) a TALE DNA-binding domain positioned at the C-terminal position, wherein a first amino acid of the TALE DNA-binding domain begins 136 amino acids upstream from a first amino acid of the at least one RVD DNA-binding repeat domain.

### Claim 15

An isolated nucleic acid sequence encoding a chimeric recombinase DNA-recombination target-sequence comprising, in a 5′ to 3′ orientation:
a) a first TALE binding site;
b) a TALER central sequence comprising, in a 5′ to 3′ orientation:
i) an optional first spacer sequence;
ii) a recombinase core sequence; and
iii) an optional second spacer sequence; and
c) a second TALE binding site.

### Claim at position 16

16-19. (canceled)

### Claim 20 (depends on 1)

A chimeric recombinase polypeptide dimer comprising:
a) a first chimeric recombinase polypeptide according to claim 1 binding with a first chimeric recombinase DNA recombination target sequence; and
b) a second chimeric recombinase polypeptide according to claim 1 binding with the first recombinase DNA recombination target sequence, wherein the first chimeric recombinase polypeptide and the second chimeric recombinase polypeptide form a dimer.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A chimeric recombinase polypeptide tetramer comprising:
a) a first pair of chimeric recombinase polypeptides according to claim 1 binding with a first chimeric recombinase DNA recombination target sequence; and
b) a second pair of chimeric recombinase polypeptides according to claim 1 binding with a second chimeric recombinase DNA recombination target sequence, wherein the first pair of chimeric recombinase polypeptides and the second pair of chimeric recombinase polypeptides form a tetramer.

### Claim at position 20

23-24. (canceled)

### Claim 25 (depends on 1)

A method of gene-targeting comprising binding a chimeric recombinase DNA-recombination target-sequence with at least two chimeric recombinase polypeptides according to claim 1.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A method of gene-targeting comprising:
a) binding a first pair of chimeric recombinase polypeptides according to claim 1 with a first chimeric recombinase DNA recombination target sequence; and
b) binding a second pair of chimeric recombinase polypeptides with a second chimeric recombinase DNA recombination target sequence, wherein the first pair of chimeric recombinase polypeptides and the second pair of chimeric recombinases polypeptides form a tetramer, and wherein the tetramer mediates recombination between the first and the second chimeric recombinase DNA recombination target sequences.

### Claim at position 24

28-47. (canceled)

### Claim 48

A method of gene-targeting in a cell comprising introducing one or more chimeric recombinase polypeptides and one or more gene-targeting donor constructs comprising one or more TALER recombination sites into a cell, wherein a recombinase core sequence of one or more of said TALER recombination sites differs by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 bp as compared to a recombinase core sequence in a genome of said cell.

### Claim at position 26

49-53. (canceled)
